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HIGHLIGHTS 
• FcµR binds with similar affinity to pentameric IgM, IgM-Fc homodimer and IgM-Fc lacking 
the Cµ2 domains  
• Each IgM heavy chain can bind one receptor molecule 
• A single mutation in the Cµ4 domain of IgM abrogates receptor binding   
ABSTRACT  
FcµR is a high-affinity receptor for the Fc portion of human IgM. It participates in B cell activation, 
cell survival and proliferation, but the full range of its functions remains to be elucidated. The receptor 
has an extracellular immunoglobulin (Ig)-like domain homologous to those in Fcα/µR1 and pIgR, but 
unlike these two other IgM receptors which also bind IgA, FcµR exhibits a binding specificity for only 
IgM-Fc. Previous studies have suggested that the IgM/FcµR interaction mainly involves the Cµ4 
domains with possible contributions from either Cµ3 or Cµ2. To define the binding site more precisely, 
we generated three recombinant IgM-Fc proteins with specific mutations in the Cµ3 and Cµ4 domains, 
as well as a construct lacking the Cµ2 domains, and analyzed their interaction with the extracellular Ig-
like domain of FcµR using surface plasmon resonance analysis. There is a binding site for FcµR in each 
IgM heavy chain. Neither the absence of the Cµ2 domains nor the  quadruple mutant 
D340S/Q341G/D342S/T343S (in Cµ3 adjacent to Cµ2) affected FcµR binding, whereas  double mutant 
K361D/D416R (in Cµ3 at the Cµ4 interface) substantially decreased binding, and a single mutation 
Q510R (in Cµ4) completely abolished FcµR binding. We conclude that glutamine at position 510 in 
Cµ4 is critical for IgM binding to FcµR. This will facilitate discrimination between the distinct effects 
of FcµR interactions with soluble IgM and with the IgM BCR. 
 
                                               
1 Abbreviations: Fca/µR, IgA/IgM Fc receptor; pIgR, polymeric immunoglobulin receptor; sIgFcµR, 
soluble extracellular immunoglobulin-like domain of FcµR; BCR, B cell receptor; IgM-Fc, dimer of 
Cµ2-Cµ3-Cµ4 domains; Fcµ3-4, dimer of Cµ3-Cµ4 domains; SEC-MALLS, size exclusion 
chromatography-multi-angle laser light scattering; SPR, surface plasmon resonance; CD, circular 
dichroism; RU, resonance unit in SPR; Rmax, maximum RU value; HEK, human embryonic kidney 
cells; IPTG, isopropyl β-D-1-thiogalactopyranoside.  
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The binding of immunoglobulins to their receptors via the Fc domains is key to expressing effector 
functions that are essential in host defense. Identification of the binding sites for these receptors on 
immunoglobulin Fc regions is therefore critical for understanding the molecular pathways through 
which they act.   
Until the year 2000, the only known human IgM-Fc receptor was polymeric immunoglobulin receptor 
(pIgR), which binds both IgM and IgA and is expressed on basolateral surfaces of mucus epithelium 
and ducts of secretory glands  [1]. A second receptor, designated Fcα/µR and expressed on follicular 
dendritic cells, macrophages and lymphocytes in humans [2,3], also binds IgM and IgA [4,5]. The 
recently discovered human FcµR [6] also referred to as FAIM3 or TOSO, is a high-affinity human IgM-
Fc receptor expressed on B cells, T cells  and a subset of NK cells [7-9]. The functions of FcµR are yet 
to be fully explored [10,11] but the receptor is thought to be involved in tonic signalling, early B cell 
activation and regulation of B cell-mediated T cell immunity [12-16]. 
FcµR is a 390-amino acid (aa) polypeptide consisting of a 17-aa signal peptide and 107-aa Ig-like 
domain, followed by a further 127-aa extracellular region, a 21-aa transmembrane portion that has a 
charged histidine residue and a 118-aa cytoplasmic tail. The receptor has no N-linked glycosylation site 
[7,17], however, O-linked glycosylation in the stalk region has been reported [18]. 
The present study focuses on the FcµR binding properties of IgM-Fc. We generated the recombinant 
extracellular Ig-like domain of human FcµR (sIgFcµR), IgM-Fc with and without the Cµ2 domains, 
and IgM-Fc with site-directed mutations, for binding analysis by surface plasmon resonance (SPR), to 
identify the structural determinants of IgM-Fc responsible for FcµR binding.  
Previous work has shown that the Cµ3 and Cµ4 domains of polymeric IgM are involved not only in 
binding FcµR [6], but also the human pIgR and Fcα/µR receptors [1,19,20]. Using a panel of domain-
swapped antibodies, a recent study [21] identified the Cµ4 domain as the dominant region of IgM-Fc 
for FcµR binding, with a minor contribution from the Cµ2 and/or the Cµ3 domains; molecular dynamics 
simulations of models of this interaction favoured involvement of Cµ2 residues together with Cµ4 [21]. 
We now report studies using site-directed mutagenesis and fragments of IgM-Fc to map more precisely 
the FcµR binding site and assess the contributions of the Cµ2, Cµ3 and Cµ4 domains.  
2. Material and methods 
2.1 Cloning and expression of sIgFcµR  
The cloned receptor in Zero Blunt TOPO was kindly provided by Prof. H. Kubagawa. The coding 
sequence for the extracellular Ig-like domain was cloned into the plasmid expression vector pET24+ 
and expressed in BL21 (DE3) competent cells at 37 °C under the control of the T7 promoter.  The 
oligonucleotides used were 5'-TGAGATCCGGCTGCTAACAAAG-3’  and 3'-
TAAAACAAATTGAAATTCTTCCTCTATATGTA-5’. Cells were cultured in 1 L of ampicillin-
supplemented (50 µg/mL) LB broth and grown at 37 ºC with orbital shaking at 225 rpm.  At an OD600 
between 0.6 and 0.8, isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration 
of 1 mM to induce protein expression. The cells were grown overnight at 37 °C and pelleted by 
centrifugation at 4000 g for 20 min at 4 °C. The supernatant was discarded, and the cell pellets were 
stored at -80 °C.  
2.2 Purification of sIgFcµR protein 
The cell pellets were thawed on ice and re-suspended in 50 mL lysis buffer (1M NaCl, 50mM Tris-
HCL, pH 7.5 and 1 tablet of Complete EDTA-free Protease Inhibitor (Roche)). The cells were then 
passed through a pre-chilled cell disrupter twice, under a pressure of 1000 psi. The disrupted cells were 
centrifuged at 16000 g for  15 min at 4 °C. The pellets were washed 5 times in 30 mL of 1 M NaCl, 50 
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mM Tris-HCL, pH 7.5 and 2% Triton-X.  After the final centrifugation, the inclusion bodies were 
dissolved with solubilization buffer (6 M guanidine hydrochloride in 0.5 M Tris acetate buffer, pH 8.6 
containing 2 mM β-mercaptoethanol), for 1 hr at 37 ºC. Insoluble contaminants were pelleted by 
centrifuging at 14000 rpm for 15 min at 4 °C, and the supernatant containing the protein collected. The 
sIgFcµR protein was slowly diluted 50-fold into ice-cold refolding buffer (0.1M Tris acetate pH 8.6, 
0.4 mM oxidized glutathione and 2 mM reduced glutathione), with rapid stirring at 4 ºC and left to stand 
for 72 hrs. Before purification, NaCl and imidazole were added to the refold solution to a final 
concentration of 0.5 M and 10 mM, respectively and the pH adjusted to between 7 and 8 using 1 M 
acetic acid. The solution was filtered with 0.45 µM membrane filter (Millipore) before purification by 
nickel column chromatography. The purity of the refolded sIgFcµR was analyzed by 18% SDS-PAGE.  
2.3 Design of IgM-Fc (Fcµ2-4) mutants 
Purified serum IgM was purchased from BBI solutions. The coding sequence for His-tagged IgM-Fc 
(Fcµ2-4) and Fcµ3-4, lacking the tail piece residues and cloned into pcDNA5/FRT, were generously 
provided by Dr Katy Doré. The plasmid containing the Fcµ2-4 sequence was the starting construct for 
all Fcµ2-4 mutagenesis (M1, M2 and M3). Mutations were generated using the Q5 site directed 
mutagenesis kit (New England Biolabs) and verified by sequencing on both DNA strands. The 
oligonucleotides used were, for M1 K361D mutation: 5’-CTTCCTCACCGATTCCACCAAGTTG-3’ 
and 3’-ATGCTGGCAAAGGATGGG-5’; for M1 D416R mutation: 5’-
CATCAGCGAGCGAGACTGGAATTCCGGGGAGAGGTTCAC-3’ and 3’- CTGGCCTCACCCACGGCG-5’; 
for M2 Q510R mutation: 5’-GCCTGAGCCCCGAGCCCCAGGCC-3’ and 3’- 
ATTGGGGCGCTGGTCACATAC-5’; for M3 mutations D340S, Q341G, D342S and T343S:  5’-
TCATCAGCCATCCGGGTCTTCGCC-3’ and 3’-TCCAGAGGGGACACACATGGAGGAC-5’. All primers 
for site directed mutagenesis were designed using NEBasechanger™ (New England Biolabs). 
2.4 Stable expression of IgM-Fc (Fcµ2-4) mutants 
All IgM proteins were stably transfected into human cells. HEK293 cells were seeded in 96-well plates 
to 2 x 105 cells/well and cultured overnight in a 5% CO2 incubator at 37 ºC using the transfection 
medium (Dulbecco’s modified Eagle’s medium supplemented with 10% of fetal bovine serum and 5% 
penicillin/streptomycin). The appropriate DNA was co-transfected with expression vector pOG44 (100 
ng) using Fugene tranfection reagent (Promega) following the protocol supplied by the manufacturer. 
After 48 hours, the cells were split into 24 well plates in transfection medium containing hygromycin 
B at a final concentration of 100 µg/mL. Once the cells were confluent, they were trypsinised and seeded 
into 1 L of Freestyleä serum-free medium containing 5% penicillin-streptomycin and hygromycin B 
at a final concentration of 100 µg/mL. The cells were grown in spinners for 3-4 weeks and then 
harvested. Supernatants were centrifuged at 4000 g for 30 minutes and then filtered through a 0.45 µM 
filter (Millipore). 0.1% sodium azide was added and the supernatants were stored at 4 °C. Proteins were 
first purified on an AKTA Prime system (Amersham) using nickel column chromatography and then 
on the Gilson HPLC using a Superdex 200, 10/300 column (GE Healthcare). 
2.5 Multi-angle Laser Light Scattering (MALLS) 
MALLS studies were performed in-line with SEC on mutant IgM protein samples to assess mono-
dispersity and the molecular mass of the protein samples. The peaks corresponding to the homodimeric 
Fcµ2-4 mutants from SEC were run on the Superdex 200 Increase 5/150 column (GE Healthcare) using 
an in-line miniDAWN multi-angle light scattering detector and an Optilab DSP Interferometric 
Refractometer (Wyatt Technology). The data were analysed using the ASTRA 4.9 software (Wyatt 
Technology). 
2.6 Circular dichroism (CD) analysis  
Far-UV (190-280) CD spectra were acquired on a Chirascan Plus spectropolarimeter (Applied 
Photophysics Ltd) flushed continuously with pure evaporated nitrogen throughout the experiments. 
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Measurements were recorded in a 0.5 mm strain-free rectangular cell using a 2 nm spectral bandwidth, 
1 nm step-size and 1 sec measurement time-per-point. The concentrations of the protein samples used 
ranged between 0.1 mg/mL - 0.4 mg/mL and buffer used was 10 mM HEPES and 150 mM NaCl at pH 
7.4. All spectra were acquired at 25 °C and buffer baseline corrected before analysis. 
2.7 Surface plasmon resonance (SPR) analysis  
All SPR assays were performed on a Biacore T200 instrument (Biacore, Uppsala, Sweden) at 25 °C in 
running buffer (0.01 M HEPES, 0.15 M NaCl and 0.005% Surfactant P20, pH 7.4). Serum IgM, IgM-
Fc, Fcµ3-4 and IgM-Fc (Fcµ2-4) mutants were immobilized on Biacore CM5 chips in 10 mM sodium 
acetate, pH 4.5, using standard amine coupling chemistry. The analyte was sIgFcµR in concentrations 
ranging from 0.25 µM – 12 µM. In each experiment, the binding curves were corrected by subtracting 
the signal obtained from the control flow cell. Non-specific binding was less than 30%. Steady state 
binding curves were analyzed using Biacore T200 evaluation software. The errors in the KD values 
represent the fitting of the 1:1 binding model to the experimental data.  
To investigate the stoichiometry of sIgFcµR binding to IgM or its homodimeric fragments, the 
following equation was used to calculate the activity of the immobilized IgM or fragments (which can 
be up to 100%, depending on whether any is damaged or misoriented by immobilization): 
% Activity = 100 x (Mol. Wt. of IgM or homodimeric fragment x Rmax of sIgFcµR bound)/ (Mol. Wt. 
of sIgFcµR x RU of IgM or homodimeric fragment immobilized).    
3. Results  
The extracellular Ig-like domain of human FcµR (sIgFcµR) was expressed as described in Material and 
Methods. After affinity purification, SEC was conducted to ensure the purity of the protein (Figure 1A). 
Fractions from the main peak were collected and further checked by analytical SEC before SPR 
analysis; the fraction used co-migrated in SEC with cytochrome c (molecular weight 12.4 kDa). The 
far-UV CD spectrum showed a characteristic β-sheet signature of a folded polypeptide with a broad 
minimum near 218 nm (Figure 1B). SPR analysis of sIgFcµR binding to IgM, IgM-Fc (also termed 
Fcµ2-4, consisting of two each of the Cµ2, Cµ3 and Cµ4 domains) and Fcµ3-4 (lacking the Cµ2 
domains), yielded KD values of 2.49 ± 0.54 µM, 1.15 ± 0.07 µM and 1.09 ± 0.09 µM respectively 
(Figure 2). This showed that neither pentamerisation, presence of the Fabs nor the Cµ2 domains 











Figure 1. Preparation and characterization of FcµR Ig binding domain (sIgFcµR). 
sIgFcµR protein was purified by SEC (panel A) and analysed using far-UV CD 
spectroscopy at 0.1 mg/mL (panel B).  
 


























FcµR binding site on IgM 
 
 5 
SPR has limitaitons as a method to determine the absolute stoichiometry between, in this case, an 
antibody or fragment and its receptor, due to inevitable loss of activity caused by chemical coupling of 
the antibody or fragment to the matrix. However, since the initial baseline signal in RU is proportional 
to the mass of antibody or fragment immobilizsed, and the additional signal in RU is proportional to 
the mass of receptor bound, it is possible to calculate the theoretical maximum expected signal assuimg 
a particular stoichiometry of binding. For each of the proteins, IgM, IgM-Fc and Fcµ3-4, the ratio of 
Rmax (the extrapolated maximum SPR signal for sIgFcµR binding in resonance  units, RU) to the number 
of RU immobilized on the sensor chip, taking into account the relative molecular weights (900 kDa, 76 
kD and 51 kDa respectively), indicated that each IgM heavy chain has a binding site for sIgFcµR. The 
number of RU immobilized for IgM, IgM-Fc and Fcµ3-4 was 1959, 876 and 1343 respectively, and the 
sIgFcµR Rmax values were 229, 253 and 472. If the stoichiometry of binding is assumed to be one 
sIgFcµR to one IgM-Fc homodimer, then the apparent binding activities are 165%, 171% and 139% 
respectively (see equation in Material and Methods); since no immobilized protein can have an activity 
of >100% (and it is commonly much less), this indicates that each heavy chain must be able to bind one 
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Site-directed mutagenesis was applied to study IgM-Fc binding to sIgFcµR using SPR. While there is 
currently no crystal structure for human IgM-Fc or any of its domains, assumptions about their structural 
features can be made based on the individual domain structures of mouse IgM-Fc [22] and the known 
structures of other immunoglobulin class Fc regions and their complexes. IgM and IgE are the only two 
human immunoglobulin classes with an extra pair of domains, Cµ2 and Ce2 respectively, in place of a 
flexible hinge region. Additionally, the human Cµ2-4 domains show 29% identity and 48% similarity 
to the corresponding region of human IgE at the amino acid level. Consequently, the human IgE-
Fc/sFcεRIα and IgE-Fc/sCD23 crystal structures [23,24], as well as other immunoglobulin-Fc/receptor 
structures [25, 26], were used to predict likely binding sites for FcµR in IgM-Fc. Furthermore, residues 
in IgA Ca3 have been implicated in pIgR binding [27-29], and there is an homologous loop in IgM 
Cµ4. Thus IgM-Fc residues structurally homologous to those involved in IgE-Fc/FcεRIα, IgE-Fc/CD23, 
IgA-Fc/FcαR and IgA-Fc/pIgR interactions were targeted with mutations. A striking similarity between 
the nature and location of the binding sites in IgG and IgE for their Fc receptors has been observed 
[26,30], and thus the proposition that the IgM-Fc/FcµR binding site might be structurally homologous 
to one of these interactions is not unreasonable.  
Figure 3 shows the locations of the mutations introduced into the Cµ3 and Cµ4 domains of IgM-Fc. 
Three mutant human IgM-Fc (Fcµ2-4) constructs were designed. In mutant M1, aspartic acid and 
arginine residues were introduced at positions 361 and 416 respectively (K361D/D416R). These 
residues are analogous to those critically involved in the IgE-Fc/CD23 and IgA-Fc/FcαR interactions, 
respectively. In mutant M2, a glutamine residue at position 510 was replaced by arginine (Q510R) at a 
site corresponding to the pIgR interaction with IgA-Fc. Mutant M3 involved residues 340-343 in the 
Cµ3 domain (D340S/Q341G/D342S/T343S), which correspond to critical components of the IgE-
Fc/FcεRIα and IgG-Fc/FcgR interactions.  
Figure 2. SPR analysis of sIgFcµR interaction with IgM, IgM-Fc and Fcµ3-4.  Whole 
pentameric IgM, (panel A), IgM-Fc (panel B) and Fcµ3-4 (panel C), were immobilized 
on a CM5 sensor chip and binding of sIgFcµR was determined as described in Material 
and Methods. Experiments were conducted using at least six sIgFcµR concentrations. The 













The IgM-Fc mutants were secreted from human embryonic kidney (HEK) cells. After purification by 
affinity chromatography followed by SEC (data not shown), the proteins were characterized by SEC-
MALLS and far-UV CD. Similarly, non-mutated IgM-Fc (wild-type) was prepared to act as a positive 
control in the experiments. For all four preparations, SEC-MALLS analysis revealed single peaks with 
a weight-averaged molar mass between 80 and 84 kDa, within experimental error of one another and 
of  IgM-Fc homodimer, proving that the samples were not aggregated (Figure 4).  
 
Chain A
M3 (D340S, Q341G, D342S and T343S)
Chain B





Figure 3. Schematic showing the mutation sites in the Cµ3 and Cµ4 domains. 
Homology model of human Fcµ3-4 showing the locations of mutated IgM residues 
in space-filling representation: K361D (green)/D416R (straw), Q510R (red) and the 
adjacent residues 340-343, DQDT to SGSS (purple). The IgM-Fc structure was 
predicted by the Swiss Model Server [31] using the structure of human IgE-Fc (PDB 
ID: 2WQR) as a template. 








The far-UV CD profiles of all the three IgM-Fc mutants compared well with that of wild-type, 
suggesting that the native states of the mutants were not perturbed by the respective mutations and that 






            A: WT B: M1 (K361D, and D416R)
C: M2 (Q510R) D: M3 (D340S, Q341G, D342S, T343S)
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Fig 4. Characterization of IgM-Fc wild-type and mutants, M1, M2 and M3. SEC-MALLS 
analysis of IgM-Fc wild-type (panel A) and mutants M1 (panel B), M2 (panel C) and M3 (panel 
D). The refractive index detector signal (black), and calculated molar mass (blue), are plotted as 
a function of the column elution time. 
Figure 5. Characterization of IgM-Fc wild-type (WT) and mutants, M1, M2 
and M3. Far-UV CD spectra for all four proteins are characteristic of β-sheet 
structure (all scaled to a concentration of 0.4 mg/mL).  
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SPR analysis was used to assess the binding of sIgFcµR to immobilized wild-type, single- (Q510R), 
double- (K361D/D416R) and quadruple- (D340S/Q341G/D342S/T343S) mutant IgM-Fc. The 
sensorgrams for the four IgM-Fc species and the resulting KD values for wild-type and the quadruple 








The mutation of residues 340-343 in Cµ3 generated an IgM-Fc mutant (M3) with sIgFcµR binding 
parameters (KD = 1.45 ± 0.03 µM) almost indistinguishable within experimental error from the wild-
type (KD = 1.83 ± 0.09 µM). This shows that residues D340, Q341, D342 and T343, which correspond 
to key elements of the IgE-Fc/FcεRIα and homologous IgG-Fc/FcgR interactions, play no role in the 
binding of IgM-Fc to FcµR. The double mutation of residues 361 and 416 in Cµ3 (M1) substantially 
reduced sIgFcµR binding; the location of K361 and D416 at the Cµ3/Cµ4 interface corresponds to that 
of the CD23 and FcaR binding sites in IgE and IgA respectively. (The low signal does not permit 
calculation of a reliable KD value). Further investigation with single mutations would be required to 
determine the contribution of each. Finally, mutation of residue 510 in Cµ4 (M2) showed no binding 









KD = 1.83 ± 0.09μM 















D: M3 (D340S, Q341G, D342S, T343S)
KD = 1.45 ± 0.03μM 
Concentration μM
Figure 6. SPR analysis of sIgFcµR interaction with IgM-Fc wild-type and mutants, 
M1, M2 and M3. IgM-Fc wild-type (panel A) and mutants, M1 (panel A), M2 (panel C), 
and M3 (panel D) were immobilized on a CM5 sensor chip and binding of sIgFcµR was 
determined as described in Material and Methods. Experiments were conducted using at 
least six sIgFcµR concentrations, with replicates. The KD values were generated from the 
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4. Discussion  
When the receptor FcµR was first identified, the binding region in IgM was shown to lie (principally) 
within the Cµ3 and Cµ4 domains since an Fcµ5 fragment, consisting largely of these domains, inhibited 
the interaction [6,17]. A later study with “domain-swapped” antibody Fc regions confirmed the 
involvement of the Cµ4 domain and implicated a possible contribution from either Cµ2 or Cµ3 [21]. In 
order to locate more precisely the binding site for FcµR in IgM-Fc, we produced for the first time the 
recombinant extracellular Ig-like domain of FcµR (sIgFcµR) in E. coli, and studied its binding to IgM, 
IgM-Fc, a series of IgM-Fc mutants and a sub-fragment of IgM-Fc lacking the Cµ2 domains.  
The binding of purified sIgFcµR to whole serum IgM (largely pentameric), IgM-Fc (Fcµ2-4), and the 
Fc sub-fragment Fcµ3-4, was investigated by SPR (Figure 2). It is clear that sIgFcµR interacts with 
both whole IgM and the two Fc fragments with similar binding affinities, indicating that the Cµ2 
domains do not contribute to FcµR binding. These results also show that unlike pIgR and Fca/µR 
[19,20], FcµR can bind to both homodimeric and polymeric IgM. Assuming a 1:1 stoichiometry of each 
heavy chain to sIgFcµR, a binding affinity of KD ~ 1-2.5 µΜ was determined by SPR. This is ~ 100 
fold weaker than cell surface FcµR binding to pentameric serum IgM, which is reported as KD ~ 10 nM 
[6]; the difference is presumably due to the very high effective concentration of FcµR on the cell surface 
and the possibility of simultaneously engaging more than one receptor domain (i.e. an avidity effect).  
In order to determine the FcµR binding site on IgM, we generated three IgM-Fc mutants, M1, M2 and 
M3 (Figure 3) and studied their interaction with the receptor sIgFcµR by SPR (Figure 6). Mutations in 
Cµ3 (M3, Figure 3) corresponding to the location of the high-affinity receptor FceRI in IgE-Fc, had no 
effect upon sIgFcµR binding.  In contrast, mutation Q510R in Cµ4 (M2, Figure 3) abrogated receptor 
binding completely. A glutamine residue lies within the structurally homologous loop in the Ca3 
domain of IgA-Fc, which has been implicated in the IgA-Fc/pIgR interaction [27]. A double mutation 
(K361D/D416R) in Cµ3 (M1, Figure 3), adjacent to Cµ4 in the region to which CD23 binds in IgE, and 
FcaR in IgA-Fc, also substantially reduces sIgFcµR binding. These results establish that residue Q510, 
located in an exposed loop region of Cµ4, is a key component of the binding site for FcµR that may 
also encompass an adjacent part of Cµ3.   
Lloyd et al. proposed a model of the interaction between IgM-Fc and FcµR, based upon molecular 
dynamics simulations, that involved several residues from Cµ4, but not Q510, together with a 
contribution from Cµ2 [21]. Their experimental data implicated involvement of Cµ4 with minor 
contributions from either Cµ2 or Cµ3. Our data suggest that it is Cµ3, but not Cµ2, that may be involved 
together with Cµ4. Q510 is however adjacent to Cµ4 residues in the model of Lloyd et al., and taken 
together they may define an extended binding region (Figure 7A) that could be encompassed by the 
(modelled) Ig-like domain of FcµR (Figure 7B).   
 










In cryoEM structures and models of pentameric and hexameric IgM [32-34], the Q510 loop and adjacent 
Cµ4 residues are accessible. Residues 361 and 416 however, lie at the interface between subunits in 
these polymeric structures, although they would presumably be exposed in membrane IgM expressed 
on B cells as part of the B cell receptor (BCR) for antigen. The FcµR binding site very likely overlaps 
with part of that of pIgR, by analogy to the location identified in IgA Ca3 [27-29] and the fact that Cµ4 
is involved in binding to IgM [19]; furthermore, overlap with the Fca/µR binding site is also likely 
since residues identified as involved in Fca/µR binding to IgA are located in adjacent loop regions [20].  
The functional significance of this clustering of IgM receptor binding sites in Cµ4 is unclear, although 
some different cell types which express these receptors do co-localise (e.g. FDCs and B cells in germinal 
centres or epithelial cells and B cells) and could lead to competition for IgM. However, the Cµ4 domain 
has also been identified as the binding site for the erythrocyte membrane protein pfEMP1 expressed by 
cells infected with Plasmodium falciparum [35], and interference with FcµR binding has been proposed 
as a possible means by which this malarial parasite evades the host immune system [36].  
4.1 Conclusions 
There have been contradictory findings in relation to the function of FcµR [10]. The identification of a 
critical amino-acid residue substitution in Cµ4 (Q510R) now permits the preparation of pentameric IgM 
which cannot bind FcµR; this could be used to investigate B cell reactions in which FcµR can only 
interact with the IgM BCR. Indeed, if this mutation could be effected in the IgM BCR, then the proposed 




 A   B
Figure 7. Models of Fcµ3-4 and sIgFcµR showing the proposed receptor binding site.  
Panel A: model of Fcµ3-4 showing residues suggested to play a role in the IgM-Fc/FcµR 
interaction. The hydrophobic and polar residues within the interface in the model proposed 
by Lloyd et al. [21] are coloured in blue and light purple, respectively. The residues 
K361D, D416R and Q510R reported in our study are coloured in orange, cyan and pink, 
respectively. Panel B: model of sIgFcµR. The models of Fcµ3-4 and sIgFcµR were 
predicted using the Swiss Model server [31]. The template for Fcµ3-4 was IgE-Fc (PDB 
ID: 2WQR) and for sIgFcµR the template was camelid VHH fragment (PDB ID: 5JMR). 
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interaction with FcµR and its role in B cell survival, IgM BCR expression and tonic signalling [13,15] 
could be tested directly.  
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